Relevant bibliographies by topics / The CMR

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'The CMR'

Author: Grafiati
Published: 4 June 2021
Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'The CMR.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "The CMR"

1

Reiter, Andreas, Gunay Ahmadova, Mohamad Jawhar, Andres Virchis, Tim Somervaille, Mark Williams, Bernd Schönberger, et al. "Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms." Blood 128, no. 22 (December 2, 2016): 3114. http://dx.doi.org/10.1182/blood.v128.22.3114.3114.

Full text
Abstract:
Abstract The ETV6-ABL1 fusion gene, as consequence of a t(9;12)(q34;p13), is a rare but recurrent genetic aberration found in chronic or blast phase of eosinophilia-associated myeloproliferative neoplasms (MPN-eo) and de novo acute B-cell lymphoblastic leukemias (B-ALL) or lymphoblastic T-cell lymphomas (T-LBL). Here, we sought to evaluate a) relevant clinical characteristics, b) treatment options and c) survival in 7 ETV6-ABL1 positive patients (male, n=4; median age 46 years; range 20-61). Cytogenetic analyses revealed a conventional reciprocal translocation t(9;12)(q34;p13) in 3 cases, an ins(12;9)(p13;q34q22) and a normal karyotype in one patient each, and a complex karyotype in 2 patients. In all cases, ETV6-ABL1 was confirmed by FISH analysis and/or RT-PCR. Histopathological diagnoses of the hypercellular bone marrow (BM) included atypical chronic myeloid leukemia (n=3), MPN-eo (n=3, concomitant T-LBL in one patient) or chronic myelomonocytic leukemia (n=1). In peripheral blood, all patients presented with left shifted leukocytosis (median 84 x 109/l, range 21-143) and significant (>1.5 x 109/l) eosinophilia (median 6.1 x 109/l, range 2.0-7.1) but without increased blast cells. Splenomegaly was present in 60% of patients. After a median of 3 months (range 0-6) from diagnosis, all patients were treated with a TKI (imatinib, n=5; dasatinib, n=1; nilotinib, n=1) at standard doses. On dasatinib (#2) or nilotinib (#3), 2 patients achieved a complete hematologic remission (CHR) within 3 months and complete cytogenetic remission (CCR) after 5 months (#3) or complete molecular remission (CMR) after 18 months (#2), respectively (Figure). On imatinib (n=5), 2 of 5 patients (#4 and #5) achieved a CHR within 3 months with loss of CHR after 9 (#4) and 5 months (#5), respectively. Patient #4 developed a myeloid sarcoma. After local radiation, he received an allogeneic stem cell transplant (SCT) but died 8 months later due to GvHD while in CMR. Patient #5 switched to nilotinib and achieved a CCR and CMR after 3 and 10 months, respectively. Patient #1 has not achieved a significant response after 4 months on imatinib. Patient #6 showed progressive disease within 2 months on imatinib, but achieved a rapid CHR and durable CCR and CMR on dasatinib after 13 and 14 months, respectively. Patient #7 presented with a classical myeloid/lymphoid (T-LBL) neoplasm with eosinophilia (MLN-eo) according to the WHO classification. On imatinib, a regression of lymphadenopathy, but persistence of leukocytosis and eosinophilia was observed. With increasing leukocytosis and reappearance of lymphadenopathy, the patient was switched to dasatinib (9 months), followed by nilotinib (2 months). The responses were only partial and transient and the patient died 23 months after diagnosis with myeloid blast phase (secondary acute myeloid leukemia). Overall, after a median treatment time of 22 months (range, 3-58), 4 patients are in CCR (n=1, patient #3) or CMR (n=3; patients #2, #5, #6) while on a second generation TKI and two patients (#4, #7) have died. On imatinib, none of 5 patients achieved a CCR or CMR. We conclude that a) cytogenetic analysis is an important tool for the identification of potential TK fusion genes such as ETV6-ABL1, b) ETV6-ABL1 is a candidate for incorporation into the WHO-defined subcategory ´MLN-eo´, c) patients with MPN-eo can achieve durable CHR, CCR or CMR on TKI with second generation TKI being more effective than imatinib d) close monitoring by cytogenetics, FISH and RT-PCR is recommended for early identification of inadequate response or resistance. Figure (A) responses and (B) overall survival in 7 patients with ETV6-ABL1 positive MPN-eo treated with various tyrosine kinase inhibitors.Abbreviation, CHR:complete hematologic response; CCR: complete cytogenetic response; CMR: complete molecular response; CP: chronic phase; BP: blast phase; allo SCT: allogeneic stem cell transplantation. Figure. (A) responses and (B) overall survival in 7 patients with ETV6-ABL1 positive MPN-eo treated with various tyrosine kinase inhibitors.Abbreviation, CHR:complete hematologic response; CCR: complete cytogenetic response; CMR: complete molecular response; CP: chronic phase; BP: blast phase; allo SCT: allogeneic stem cell transplantation. Disclosures Somervaille: Novartis: Consultancy, Honoraria; Imago Biosciences: Consultancy. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership.
APA, Harvard, Vancouver, ISO, and other styles
2

Proszkowiec-Weglarz, Monika, and Tom E. Porter. "Functional characterization of chicken glucocorticoid and mineralocorticoid receptors." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 298, no. 5 (May 2010): R1257—R1268. http://dx.doi.org/10.1152/ajpregu.00805.2009.

Full text
Abstract:
Glucocorticoid (GR) and mineralocorticoid (MR) receptors are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Little is known about the function of GR and MR in avian species. Recently, the chicken homologue of the GR (cGR) gene was cloned, and its tissue-specific expression was characterized, whereas the full-length sequence of the chicken MR (cMR) gene remains unknown. Therefore, the aims of this project were to clone the full-length cMR and to functionally characterize both chicken receptors. Cos-7 cells were transiently transfected with cGR or cMR expression vectors along with a glucocorticoid response element-luciferase (GRE-Luc) reporter construct. Transfected cells were then treated with increasing doses of corticosterone (CORT) or aldosterone (ALDO) alone and with GR or MR antagonists (ZK98299 and spironolactone, respectively). Transactivation of cGR or cMR was evaluated by luciferase assay. CORT and ALDO induced cGR- and cMR-driven transcriptional activity in a dose-dependent manner. Each receptor responded to both steroids, but cMR transcriptional activity was induced by lower levels of CORT and ALDO than cGR. Coexpression of both chicken corticosteroid receptors in Cos-7 cells had no synergistic or additive effect on CORT- or ALDO-induced transcriptional activity. Corticosteroid-dependent transactivation of cGR and cMR was partially blocked by antagonists. ZK98299 showed high specificity to cGR, while spironolactone had agonist properties toward both receptors. Immunocytochemistry was used to assess the cellular localization of both receptors. Corticosteroids induced translocation of both receptors into the nucleus. The functional properties of cGR and cMR determined in this study will be helpful in defining the physiological roles of GR and MR in avian species.
APA, Harvard, Vancouver, ISO, and other styles
3

Abdelaziz, Hanaa MM, Ahmed M. Tawfik, Ayman A. Abd-Elsamad, Sherif A. Sakr, and Abdulsalam M. Algamal. "Cardiac magnetic resonance imaging for assessment of mitral stenosis before and after percutaneous balloon valvuloplasty in comparison to two- and three-dimensional echocardiography." Acta Radiologica 61, no. 9 (January 14, 2020): 1176–85. http://dx.doi.org/10.1177/0284185119897368.

Full text
Abstract:
Background The experience with cardiac magnetic resonance (CMR) in mitral stenosis (MS) is limited in contrast to mitral regurgitation. Purpose To compare CMR versus 2D and 3D transthoracic (TTE) and 3D transesophgeal (TEE) echocardiography in assessment of rheumatic MS before and after percutaneous balloon mitral valvuloplasty (PBMV). Material and Methods Twenty consecutive symptomatic patients with MS were evaluated prospectively and independently by CMR, TTE, and TEE pre-PBMV, and by CMR and TTE post-PBMV. Mitral valve area (MVA) was assessed by CMR planimetry, TTE and TEE planimetry, and pressure half time (PHT). Further assessment included trans-mitral velocity, mitral regurgitation (MR), and left atrial (LA) volume. Results PBMV was successful in 18 patients and failed in two patients (one with MVA <1.5 cm2, one developed severe MR). Pre-PBMV and MVA by CMR, 2D TTE, biplane, 3D TTE, 3D TEE, and PHT were 1.16, 1.16, 1.10, 1.02, 1.05, and 0.99 cm2, respectively. Post-PBMV, a significant increase in MVA was observed (2.15, 2.06, 2.07, 2.04, and 2.03 cm2, respectively). High agreement was observed between CMR and echocardiography before and after PBMV, except for PHT method. CMR significantly underestimated trans-mitral velocity and gradients compared to echocardiography (P<0.001). Before PBMV, mild MR was observed in 11, 12, and 19 patients by 2D TTE, 3D TTE, and CMR. After PBMV, MR was observed in all patients (19 mild, one severe) by all modalities. Echocardiography significantly underestimated LA volume compared to CMR (P<0.001). LA volume decreased significantly after PBMV (P<0.001). Conclusion CMR provides comprehensive assessment of several parameters in MS patients before and after intervention. Agreement with echocardiography is acceptable.
APA, Harvard, Vancouver, ISO, and other styles
4

Chiaretti, Sabina, Antonella Vitale, Loredana Elia, Anna Lucia Fedullo, Silvana Albino, Alfonso Piciocchi, Paola Fazi, et al. "Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification." Blood 126, no. 23 (December 3, 2015): 81. http://dx.doi.org/10.1182/blood.v126.23.81.81.

Full text
Abstract:
Abstract Introduction: Management of Ph+ ALL has changed since the introduction of tyrosine kinase inhibitors (TKI). We previously reported the preliminary findings of the GIMEMA LAL 1509 total therapy protocol, based on dasatinib plus steroids administration as induction therapy (Chiaretti et al, ASH 2014). The updated results on overall survival (OS), disease-free survival (DFS) and the impact of a genetic-based prognostic stratification are hereby provided. Methods: Steroids were administered from day -6 to day 31. Dasatinib (140 mg/day) was given between days 1 and 84. Patients reaching a complete molecular response (CMR, i.e. BCR/ABL1 to ABL1 ratio=0) at the end of induction (day 85) continued Dasatinib. Patients in complete hematologic remission (CHR), but not in CMR, underwent chemotherapy (clofarabine-cyclophosphamide) and/or an allogeneic transplant (HSCT), according to eligibility and donor availability. Dasatinib was administered until disease progression. Molecular testing was used to identify the presence of the BCR/ABL1 transcript on bone marrow samples, to define the fusion protein and to quantify BCR/ABL1 levels at baseline and follow-up (FU). Mutational screening was performed in relapsed cases, based on material availability. SNP array analysis was carried out using the Cytoscan HD arrays (Affymetrix, Santa Clara, CA) to identify genomic aberrations. Results: 60/63 enrolled patients were eligible. Median age was 41.9 years (range 18.7-59.1), 34 were males and 26 females; median WBC count was 12.5 x 109/l (range 1.4-178.0); the p190 fusion product was detected in 33 patients, p210 in 18 and p190/p210 in 9. Median FU is 28.4 months (range 4.2-43.7). After the steroid pre-phase, 38 patients (63%) had a blast reduction ≥75%. At day 85, 58 patients were in CHR (97%), while 2, in CHR at day 57, lost it: both harbored the p210 fusion transcript. They both returned into CHR following chemotherapy. A sustained CMR was obtained in 11 patients (18.6%): 72% had a p190 fusion transcript. No deaths in induction occurred. Among the CMR patients, only 1 experienced a hematologic relapse, which carried a T315I mutation. Of the 46 non-CMR cases, 14 relapses occurred, 8 of which in p210+ patients. Overall, there have been 12 deaths in CHR. OS is 58.3% (95%CI: 44.4-76.3) at 36 months and DFS at 30 months is 48.9% (95%CI: 36.8.0-64.9). A better DFS was observed in patients who obtained a CMR compared to cases with minimal residual disease (MRD) at day 85 (75% vs 44%, p=0.06), and in p190+ vs p210+ patients (57.1% vs 39.6%, p=ns). Mutational screening, performed in 7/15 cases at hematologic relapse detected mutations in 5: 3 T315I and 2 V299L, of which 1 with a concomitant F317I and F317L. SNP array analysis, performed in 39 cases with available DNA, showed that the most frequent aberrations were deletions of IKZF1 (85%), PAX5 (38%), CDKN2A/B (33%), MLLT3 (33%), RB1 (28%) and JAK2 (28%). While IKZF1 deletions alone did not impact on CHR or CMRachievement and DFS, a significantly worse DFS (p=0.01) and increased cumulative incidence of relapse (CIR, p=0.024) were observed in cases harboring deletions of IKZF1 plus CDKN2A/B and PAX5 (DFS: 40% vs 65% at 18 months; CIR: 40% vs 14% at 18 months (Fig. 1A and B). The relevance of this finding was further refined by stratifying patients according to the fusion protein: the impact of IKZF1 plus CDKN2A/B and PAX5 deletions is prognostically relevant in p190+, but not in p210+ patients, possibly because of the worse outcome of the latter group (Fig. 2). Finally, this analysis identified a set of genes specifically deleted in CMR cases; investigations are ongoing on additional cases to validate their potential role in predicting response to TKI. Conclusions: In this updated analysis of the GIMEMA 1509 trial, we confirm the effectiveness of a chemo-free induction in inducing CHR in almost all adult Ph+ ALL patients (97%) and CMR in a subgroup of cases (18.6%). OS and DFS at 36 months and 30 months, approaching 60% and 50%, are encouraging. More importantly, CMR achievement at day 85 is associated with extremely promising results, being 75% at 30 months, underlying that CMR should be regarded as a primary endpoint in Ph+ ALL. We confirm that p210+ patients may require an intensified approach, given the lower rate of CMR achievement and the higher relapse rate. Finally, we provide evidence that a broader genetic characterization at diagnosis allows a more refined prognostic stratification of Ph+ ALL patients. Disclosures Martinelli: Pfizer: Consultancy; Ariad: Consultancy; AMGEN: Consultancy; BMS: Consultancy, Speakers Bureau; ROCHE: Consultancy; MSD: Consultancy; Novartis: Consultancy, Speakers Bureau. Foà:Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.
APA, Harvard, Vancouver, ISO, and other styles
5

George, Sarah, Laura Horvath, Robert Molokie, John Berry, Damiano Rondelli, and Ronald Hoffman. "Response to Therapy with Imatinib Mesylate in Patients with CML Is Poor in Non-Caucasian Patients." Blood 104, no. 11 (November 16, 2004): 2937. http://dx.doi.org/10.1182/blood.v104.11.2937.2937.

Full text
Abstract:
Abstract Imatinib mesylate is a targeted therapy for chronic myeloid leukemia (CML). All phases of CML are susceptible to imatinib, with more durable responses occurring in patients in chronic phase. Studies in patients with chronic phase CML who have been treated with imatinib have shown a complete hematologic remission (CHR) rate of 97%, a complete cytogenetic remission (CCR) rate of 70%, and a complete molecular remission (CMR) rate of 10%. Racial and ethnic differences have not been extensively studied in relation to cancer outcomes, and no studies to date have demonstrated a difference in outcomes based upon race or ethnicity of patients with CML treated with imatinib. Methods : A retrospective chart review of patients with CML who have been treated with imatinib at the University of Illinois, the Westside VA, and MacNeal hospitals over the past 3 years was performed. Primary endpoints were rates of CHR, CCR, and CMR in Caucasian (C) and non-Caucasian (NC) patients with CML on treatment with imatinib. A secondary endpoint was the correlation of Sokal scores at initiation of imatinib with rates of CHR, CCR, and CMR. Results: 26 charts were reviewed of 7 C and 19 NC patients ( 12 African American, 5 Latino, 1 Indian, 1 Lebanese) in chronic phase CML. For C patients at the initiation of imatinib, mean age was 46 (45 for NC) and mean Sokal score was 0.79 (0.75 for NC). 32% (8/25) of patients had cytogenetic abnormalities in addition to the Philadelphia chromosome, all of whom were NC (50% were pretreated; 29% obtained CCR). Mean duration from diagnosis to treatment with imatinib was 5 months for C and 9 months for NC. Mean length of follow up while on imatinib was 28 months for C and 14 months for NC, with early termination due to lack of follow up, progression of disease, and death. 31% (8/26) of patients (25% C, 75% NC) had received prior treatments with agents such as IFN, AraC, busulfan, anagrelide, homoharrington, and allogeneic SCT. 100% of pretreated C had CCR (vs 33% of pretreated NC). CHR rate was 100% in C (4/4) vs. 87.5% (14/16) in NC. CCR was obtained in 100% of C (6/6) but only 14% (2/14) of NC. CMR rate was noted to be 33% (1/3) in Caucasians compared to 8.3% (1/12) in NC. Low risk Sokal scores were associated with CHR rate of 100% in C (3/3) and 75% (6/8) in NC, as well as CCR rate of 100% in C (5/5) and only 25% (2/8) in NC. Conclusions: NC patients have a poorer response to treatment with imatinib for CML. The discrepancy between complete response rates (most notably the CCR rate) between C and NC patients could be accounted for by differences in the genetic characteristics of the disease, metabolism, or adherence rates. NC patients with low risk Sokal scores also had poorer complete response rates than C patients with the same risk scores. Prospective studies are needed to further evaluate these differences and discern their etiology. Given poor CCR rates, NC patients should be HLA typed soon after diagnosis and considered for transplant if a matched donor is available.
APA, Harvard, Vancouver, ISO, and other styles
6

Hanson, Laura B., James B. Grand, Michael S. Mitchell, D. Buck Jolley, Bill D. Sparklin, and Stephen S. Ditchkoff. "Change-in-ratio density estimator for feral pigs is less biased than closed mark - recapture estimates." Wildlife Research 35, no. 7 (2008): 695. http://dx.doi.org/10.1071/wr08076.

Full text
Abstract:
Closed-population capture–mark–recapture (CMR) methods can produce biased density estimates for species with low or heterogeneous detection probabilities. In an attempt to address such biases, we developed a density-estimation method based on the change in ratio (CIR) of survival between two populations where survival, calculated using an open-population CMR model, is known to differ. We used our method to estimate density for a feral pig (Sus scrofa) population on Fort Benning, Georgia, USA. To assess its validity, we compared it to an estimate of the minimum density of pigs known to be alive and two estimates based on closed-population CMR models. Comparison of the density estimates revealed that the CIR estimator produced a density estimate with low precision that was reasonable with respect to minimum known density. By contrast, density point estimates using the closed-population CMR models were less than the minimum known density, consistent with biases created by low and heterogeneous capture probabilities for species like feral pigs that may occur in low density or are difficult to capture. Our CIR density estimator may be useful for tracking broad-scale, long-term changes in species, such as large cats, for which closed CMR models are unlikely to work.
APA, Harvard, Vancouver, ISO, and other styles
7

El Ghannudi, Soraya, Philippe Germain, Gerlinde Averous, Afshin Gangi, Thomas H. Schindler, and Alessio Imperiale. "PET/CMR." JACC: Cardiovascular Imaging 13, no. 5 (May 2020): 1270–75. http://dx.doi.org/10.1016/j.jcmg.2019.09.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hehlmann, Rüdiger, Michael Lauseker, Benjamin Hanfstein, Martin C. Müller, Annette Schreiber, Ulrike Proetel, Markus Pfirrmann, et al. "Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV." Blood 120, no. 21 (November 16, 2012): 67. http://dx.doi.org/10.1182/blood.v120.21.67.67.

Full text
Abstract:
Abstract Abstract 67 Dose optimized imatinib (IM) at doses of 400– 800mg has been shown to induce faster and deeper cytogenetic and molecular – responses than standard IM (400mg/day). Since complete molecular remission (CMR 4.5) identifies a subgroup of patients who may stay in remission even after discontinuation of treatment, it was of interest to analyse whether CMR 4.5 is reached faster with dose optimized IM and whether CMR 4.5 correlates with survival. CMR 4 and CMR 4.5 are defined as ≤ 0.01% BCR-ABL IS or ≥ 4. log reduction and ≤ 0.0032% BCR-ABL IS or ≥ 4.5 log reduction, respectively, from IRIS baseline as determined by real-time PCR. CML-Study IV is a five arm randomized study of IM 400 mg vs IM 400 mg + IFN vs. IM 400 mg + Ara C vs. IM after IFN failure vs. IM 800 mg. In the IM 800 arm, a 6 weeks run in period at IM 400 mg was followed by a dose increase to 800 mg and then by a dose reduction according to tolerability. Grade 3 or 4 adverse effects (AE) were to be avoided. From July 2002 to March 2012 a total of 1551 patients with newly diagnosed chronic phase CML were randomized of whom 1525 were evaluable. Median age was 52 years, 88% were EUTOS low risk, 12% high risk, 36% were Euro score low risk, 52% intermediate and 12% high risk, 38% were Sokal low risk, 38% intermediate and 24% high risk. 113 patients were transplanted, 246 received 2nd generation TKI. 152 patients have died, 90 of CML or unknown reasons, 62 of not directly CML-related causes. After a median observation time of 67,5 months 6 years OS was 88.2% and PFS 85.6%. CCR, MMR, CMR 4 and CMR 4,5 were achieved significantly faster with dose optimized IM (400 – 800 mg). No significant differences in remission rates were observed between IM 400 mg and the combination arms IM 400 mg + IFN and IM 400 mg + Ara C, whereas IM after IFN failure thus far yielded significantly slower response rates. After 4 years CCR rates were for IM 400, IM 400 + IFN, IM 400 + Ara C, IM 400 after IFN, and IM 800, 80%, 75%, 73%, 59% and 80%, respectively, MMR rates 84%, 77%, 82%, 61% and 88%, CMR 4 rates 57%, 55%, 55%, 40% and 65%, and CMR 4.5 rates 40%,42%, 42%, 28% and 52%, respectively. CMR 4 was reached after a median of 27 months with IM 800 and 41.5 months with IM 400. CMR 4.5 was reached after a median of 41.5 months with IM 800 and 63 months with IM 400. EUTOS low risk patients reached all remissions faster than EUTOS high risk patients. The differences of CMR 4 rates between IM 800 and IM 400 at 3 years were 13% and at 4 years 8%, and of CMR 4.5 rates at 3 years 10% and at 4 years 13%. Grade 3 and 4 AE were not different between IM 400 and dose optimized IM 800. Independent of treatment approach, CMR 4 and more clearly CMR 4.5 at 3 years predicted better OS and PFS, if compared with patients without CMR 4 or CMR 4.5, respectively. CMR 4 and 4.5 were stable. After a median duration of CMR 4 of 3.7 years only 4 of 792 patients with CMR 4 have progressed. Life expectancy with CMR 4 and 4.5 was identical to that of the age matched population. We conclude that dose optimized IM induces CMR 4.5 faster than IM 400 and that CMR 4 and CMR 4.5 at 3 years are associated with a survival advantage. Dose optimized IM may provide an improved therapeutic basis for unmaintained treatment discontinuation in patients with CML. Disclosures: Hehlmann: Novartis: Research Funding. Müller:Novartis, BMS: Consultancy, Honoraria, Research Funding. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership. Schnittger:MLL Munich Leukemia Laboratory: Equity Ownership. Hochhaus:Novartis, BMS, MSD, Ariad, Pfizer: Consultancy Other, Honoraria, Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
9

Lamure, Sylvain, François Van Laethem, Delphine De Verbizier, Claire Lozano, Eve Gehlkopf, Jean-Jacques Tudesq, Chris Serrand, et al. "Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy." Cancers 13, no. 17 (August 25, 2021): 4279. http://dx.doi.org/10.3390/cancers13174279.

Full text
Abstract:
CD19-directed CAR T-cells have been remarkably successful in treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma (t-FL). In this cohort study, we treated 60 patients with axicabtagene ciloleucel or tisagenlecleucel. Complete and partial metabolic responses (CMR/PMR) were obtained in 40% and 23% of patients, respectively. After 6.9 months of median follow-up, median progression-free survival (mPFS) and overall survival (mOS) were estimated at 3.1 and 12.3 months, respectively. Statistical analyses revealed that CMR, PFS, and OS were all significantly associated with age-adjusted international prognostic index (aaIPI, p < 0.05). T-cell subset phenotypes in the apheresis product tended to correlate with PFS. Within the final product, increased percentages of both CD4 and CD8 CAR+ effector memory cells (p = 0.02 and 0.01) were significantly associated with CMR. Furthermore, higher CMR/PMR rates were observed in patients with a higher maximal in vivo expansion of CAR T-cells (p = 0.05) and lower expression of the LAG3 and Tim3 markers of exhaustion phenotype (p = 0.01 and p = 0.04). Thus, we find that aaIPI at the time of infusion, phenotype of the CAR T product, in vivo CAR T-cell expansion, and low levels of LAG3/Tim3 are associated with the efficacy of CAR T-cell therapy in DLBCL patients.
APA, Harvard, Vancouver, ISO, and other styles
10

Karim, Md Robiul, Rongjun Wang, Haiju Dong, Longxian Zhang, Jian Li, Sumei Zhang, Farzana Islam Rume, et al. "Genetic Polymorphism and Zoonotic Potential ofEnterocytozoon bieneusifrom Nonhuman Primates in China." Applied and Environmental Microbiology 80, no. 6 (January 10, 2014): 1893–98. http://dx.doi.org/10.1128/aem.03845-13.

Full text
Abstract:
ABSTRACTEnterocytozoon bieneusiis an important zoonotic pathogen. To assess the human-infective potential ofE. bieneusiin nonhuman primates (NHPs), we examined the prevalence and genotype distribution ofE. bieneusiin 23 NHP species by PCR and sequence analysis of the ribosomal internal transcribed spacer (ITS). A total of 1,386 fecal specimens from NHPs from five provinces in China were examined, andE. bieneusiwas detected in 158 (11.4%) specimens from five NHP species, including cynomolgus monkey (67.7%), rhesus macaque (8.8%), Japanese macaque (33.3%), white-headed langur (13.6%), and golden snub-nosed monkey (3.5%) (P< 0.0001). The infection rates were 70.2%, 21.5%, 8.5%, 7.5%, and 5.6% in Guangdong, Yunnan, Guangxi, Henan, and Sichuan Provinces, respectively (P< 0.0001). The prevalence was significantly higher in captive (13.7%) than in free-range (5.0%) animals (P< 0.0001). Altogether, 16 ITS genotypes were observed, including nine known genotypes (IV, D, Henan V, Peru8, PigEBITS7, EbpC, Peru11, BEB6, and I) and seven new genotypes (CM1 to CM7). The common genotypes included CM1, IV, and D, which were detected in 43, 31, and 30 specimens, respectively. Phylogenetic analysis revealed that seven known genotypes (but not BEB6 and I) and four new genotypes (CM1, CM2, CM3, and CM6) belonged to the previously described group 1 with zoonotic potential. Genotypes CM5 and CM7 clustered with group 2, whereas genotype CM4 did not belong to any of the previously proposed groups. It was concluded that humans and NHPs residing in the same geographical location shared the sameE. bieneusigenotypes, indicating a potential role of these animals in the zoonotic transmission ofE. bieneusi.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "The CMR"

1

Pohl, Annika. "Sol−Gel Synthesis of CMR Manganites." Doctoral thesis, Uppsala University, Department of Materials Chemistry, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3970.

Full text
Abstract:

The development of more advanced materials forms the basis of technological progress. One group of fascinating compounds with many potential applications in spintronic devices are the mixed-valence perovskite manganites. These have attracted considerable interest during the last decade through their very large magnetoresistance near the Curie Temperature. Although the properties of a material determinie any application, the development of reliable and flexible synthesis methods is crucial, as is the understanding of these methods. Knowledge of how different materials are formed is also of general importance in tailoring new materials. The aim of this project has therefore been not only to develop a new synthesis route, but also to understand the mechanisms involved.

This thesis describes the synthesis and characterization of a novel manganese alkoxide and its use in sol–gel processing of magnetoresistive perovskite manganites. In searching for a soluble manganese alkoxide for sol–gel processing, we found that the methoxy-ethoxide, [Mn19O12(moe)14(moeH)10]·moeH, has a high solubility in appropriate organic solvents. Being 1.65 nm across, it is one of the largest alkoxides reported; it is also of interest because of its (for oxo-alkoxides) rare planar structure. After mixing with La, Nd, Ca, Sr, and Ba methoxy-ethoxides, [Mn19O12(moe)14(moeH)10]·moeH was used in the first purely alkoxide based sol–gel processing of perovskites manganites. The phase evolution on heating xerogel powders to 1000°C was studied, and thin films were prepared by spin-coating.

It was found that the easily oxidised Mn-alkoxide facilitates the formation of high oxygen-excess modifications of the perovskites. The reactive precursor system yields fully hydrolysed gels almost without organic residues, but the gel absorbs CO2 from the air, leading to carbonate formation. The carbonate decomposition is the limiting step in oxide formation. Transport measurements of La0.67Ca0.33MnO3 films on LaAlO3 substrate show that all-alkoxide sol–gel derived films can compete with PLD films in terms of quality of epitaxy and transport. The somewhat different behaviour of the sol–gel derived films compared to PLD films is attributed to differences in morphology and oxygen stoichiometry.

APA, Harvard, Vancouver, ISO, and other styles
2

Vacek, Tomáš. "Úloha nákladního listu CMR v přepravních službách." Master's thesis, Vysoká škola ekonomická v Praze, 2011. http://www.nusl.cz/ntk/nusl-162838.

Full text
Abstract:
The first part of this thesis is devoted to the General Convention of CMR, CMR consignment note, obligatory data which are necessary to write in and to the parties acting on the transport market. The second part will focus on the carrier's liability as same as liability of other parties, insurance carrier's liability for loss, damage or destruction of the consignment, lapse, complaint and insurance. This issue will be demonstrated and will discuss with the court decisions. The next section will be described and analyzed electronic CMR. This section tries to evaluate the positives and negatives of its use in practice and its future. In particular, this part will be engaged in research which has implemented among members by the International Road Transport Union.
APA, Harvard, Vancouver, ISO, and other styles
3

Malde, Nishil. "Raman spectroscopy of manganite (CMR) andcuprate (HTS) oxides." Thesis, Imperial College London, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.270622.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bhamra-Ariza, Paul. "The measurement of absolute myocardial perfusion in patients with coronary artery disease using 3T CMR and 1.5T CMR : validation against PET." Thesis, Imperial College London, 2011. http://hdl.handle.net/10044/1/9749.

Full text
Abstract:
Objectives: To validate absolute measurement of myocardial blood flow (MBF) with 1.5 Tesla (T) and 3T cardiovascular magnetic resonance (CMR) using positron emission tomography (PET) as the gold standard. Methods: 21 healthy subjects and 44 patients with coronary artery disease (CAD) were randomised to undergo PET scanning using oxygen 15-labeled water and CMR scanning at either 1.5T or 3T, using a saturation recovery fast-gradient echo sequence and 0.04 mmol/kg gadolinium bolus. MBF was assessed at rest and during adenosine stress. CMR MBF was determined by model independent deconvolution Results: There was no significant difference in rest and stress rate pressure product during PET and CMR scanning at either field strength. Agreement between the two methods was tested by Bland Altman plots The mean difference between PET MBF and 3T CMR MBF was 0.30 ml/g/min, limits of agreement of -1.23 and 1.89 ml/g/min. For the 3T cohort the sensitivity and specificity for the detection of coronary stenoses ≥50 % was 87% and 81 % for PET (threshold 1.93 ml/g/min) and 61% and 78% (threshold 1.73 ml/g/min) for 3T CMR. The mean difference between PET and 1.5T CMR was 0.05 ml/g/min, limits of agreement of -1.75 and 1.84 ml/g/min. For the 1.5T cohort the sensitivity and specificity for the detection of coronary stenoses ≥50 % was 84% and 94% for PET (threshold 1.98 ml/g/min) and 81% and 78% (threshold 2.29ml/g/min) for CMR. Conclusion: This study demonstrates there is no significant difference in mean MBF as measured by PET and CMR at either 1.5T or 3T CMR. However there is marked variation in values of MBF between different segments as demonstrated by the wide limits of agreements.
APA, Harvard, Vancouver, ISO, and other styles
5

Teo, Bee San. "A study of colossal magneto-resistance (CMR) thin films." Thesis, University of Cambridge, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.625076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dall'Armellina, Erica. "Applications of 3T CMR in acute coronary syndromes (ACS)." Thesis, University of Oxford, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.589619.

Full text
Abstract:
Introduction There is a pressing clinical need to treat patients with acute coronary syndrome (ACS) timely and efficiently in order to improve their prognosis. Standard tools available in ED, while useful, do not comprehensively characterize ACS for either diagnosis or risk stratification. The role of CMR in ACS is emerging because it allows assessment of both myocardial composition and function. Newer CMR techniques such as: a) T2 W imaging for assessing myocardial oedema and area at risk B) pre contrast T1 mapping techniques for quantitative characterization of the tissue composition, are adding further utility for CMR in ACS. At present the clinical use of these techniques is still limited and further investigations are needed to assess their clinical applicability in ACS patients. Aims The aims of this thesis were several. Firstly we sought to establish a CMR protocol for imaging ACS patients on a 3T CMR scanner. In order to do so, we validated a novel T2 W technique for oedema imaging (T2 prep SSFP) at 3T. Second, we aimed to perform a detailed study of the time course of oedema in ACS patients in order to establish the appropriate imaging time for the assessment of area at risk. Third, by applying T2W acute oedema imaging, we sought to investigate the functional and pathological meaning of complicated remote plaques in patients with multivessel disease. Finally, we aimed to establish whether, in comparison to standard CMR techniques, novel precontrast Tl mapping allows better characterisation of the acutely injured myocardium and whether it can predict long-term functional recovery. Methods The research studies were all performed on a 3T Trio Siemens scanner. In the initial stage of the research, we validated the T2 W technique performing phantom work and scanning both volunteers and patients to assess the uniformity of signal intensity in the myocardium and to establish a threshold based method to post process the images. We then established a CMR protocol for ACS including oedema imaging, T1 mapping imaging, perfusion, functional and late gadolinium enhancement imaging. Patients with acute myocardial infarction (both ST elevation myocardial infarction (STEMI) and non STEMI) were scanned at 4 different time points after the acute event (3 scans within 2 weeks and one at 6 months). All STEMI patients underwent primary percutaneous coronary intervention (PCI) while the non-STEMI patients underwent coronary angiography and for PCI. Results We validated the T2prep SSFP technique at 3T, highlighting its limitations and establishing a threshold of mean ± 2SD to assess myocardial oedema. We found that the optimal imaging window to assess the maximal expression of myocardial oedema was within 1 week from the acute event in patients with ST elevation MI. Also, our results showed a reduction of LGE over time (from acute to chronic) in segments which also showed improvement in contractile function indicating that even segments with transmural LGE assessed in the early hours post event could be viable. By applying these techniques in acute patients with bystander disease undergoing percutaneous coronary intervention, we found that: l) T2W imaging can detect myocardial injury downstream from a vessel identified as "non culprit" 2) in 20% of NSTEMI patients, the angiographic assessment alone failed to identify the culprit vessel. Finally, we found that the diagnostic performance of acute pre-contrast Tl-mapping was at least as good as that ofT2W CMR for detecting myocardial injury. There was a significant relationship between the segmental damaged fraction assessed by either by LGE or T2W, and mean segmental Tl values and the likelihood of improvement of segmental function at 6 months decreased progressively as acute Tl values increased. Conclusions In summary, we defined a stable imaging window for the retrospective evaluation of area at risk and we also indicated that acutely detected LGE does not necessarily equate with irreversible injury and may severely underestimate salvaged myocardium. Furthermore, in NSTEMI patients with multivessel disease, by revealing acute myocardial damage in territories pertaining to vessels not treated acutely, we raised the issue of the need for better tools for the correct identification of the culprit vessel and to stratify patients rather than by angiographic assessment alone. Finally, we demonstrated how pre-contrast Tl mapping allows for assessment of the extent of myocardial damage and how Tl mapping might become an important complementary technique to LGE and T2W for the identification of reversible myocardial injury and the prediction of functional recovery in acute MI.
APA, Harvard, Vancouver, ISO, and other styles
7

Kadavá, Eva. "Vybrané problémy provozu dopravní firmy MKD." Master's thesis, Vysoká škola ekonomická v Praze, 2010. http://www.nusl.cz/ntk/nusl-81922.

Full text
Abstract:
Transport sector as a whole records growing trend, whereas road transport has recorded the biggest growth of transported goods. An increase in international trade brings more opportunities for firms involved in the haulage industry. The aim of this thesis is to show the basic requirements in order to set up the haulage and forwarding business. I will mention various factors, that influence the transport market. In other chapters I will analyze laws and treaties, which every haulage company has to adhere to. The last chapter is devoted to problems of financing truck fleet. In the end there is a summary of ways on how to tackle and reduce non-payment by clients.
APA, Harvard, Vancouver, ISO, and other styles
8

Dudinská, Lenka. "Preprava elektrických spotrebičov z Turecka do Českej republiky." Master's thesis, Vysoká škola ekonomická v Praze, 2013. http://www.nusl.cz/ntk/nusl-192977.

Full text
Abstract:
This thesis deals with problems of transportation of goods from Turkey to the Czech Republic. The goal of this thesis is to provide a comprehensive overview of geo-political, legal and economic knowledge, which could serve as a guide for small transportation companies. The overview is divided into three parts. The first part deals with multilateral agreements governing international road transport with emphasis on the CMR Convention. The second part is devoted to customs issues, in particular transit procedure. The third part deals with transport from the economic point of view. In this part, two transportation routes are proposed, which are then analysed considering time, safety and cost.
APA, Harvard, Vancouver, ISO, and other styles
9

Riemer, Jens-Berghe. "Forum-Shopping mittels negativer Feststellungsklage im Geltungsbereich von ZPO, EuGVVO und CMR /." Berlin : Dissertation.de, 2006. http://deposit.d-nb.de/cgi-bin/dokserv?id=2898623&prov=M&dok_var=1&dok_ext=htm.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gao, Feng. "Studies on the synthesis, characterization and properties of colossal magnetoresistive (CMR) materials." Access electronically, 2004. http://www.library.uow.edu.au/adt-NWU/public/adt-NWU20041217.100120/index.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "The CMR"

1

Schäffer, Utz, and Jürgen Weber, eds. CMR SH 1-2015. Wiesbaden: Springer Fachmedien Wiesbaden, 2015. http://dx.doi.org/10.1007/978-3-658-09361-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Herber, Rolf. CMR: Internationales Strassentransportrecht : Kommentar. München: C.H. Beck, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jacquier, Alexis. CMR and MDCT in Cardiac Masses. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-18457-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Welfare, Massachusetts Dept of Public. Fair information practices: 106 CMR 100-108. Boston, Mass.]: The Dept., 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Vogel, Verlag Heinrich. ADSp, SVS/RVS, KVO, CMR, AGNB, GüKUMB. München: H. Vogel, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Welfare, Massachusetts Dept of Public. Fair hearings rules: 106 CMR 343-343.370. Boston, Mass.]: The Dept., 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Clarke, Malcolm A. International carriage of goods by road: CMR. 2nd ed. London: Sweet & Maxwell, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Regnarsen, Kjeld. Lov om fragtaftaler ved international vejtransporter (CMR-loven). [Copenhagen]: Jurist- og økonomforbundet, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jesser, Helga. Frachtführerhaftung nach der CMR: Internationaler und nationaler Strassengütertransport. Wien: A. Orac, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Thume, Karl-Heinz, and Klaus Demuth. Kommentar CMR: Übereinkommen über den Beförderungsvertrag im internationalen Strassengüterverkehr. 3rd ed. Frankfurt, M: Deutscher Fachverlag GmbH, Fachmedien Recht und Wirtschaft, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "The CMR"

1

Abbasi, Adeel, Francis DeRoos, José Artur Paiva, J. M. Pereira, Brian G. Harbrecht, Donald P. Levine, Patricia D. Brown, et al. "CMR." In Encyclopedia of Intensive Care Medicine, 568. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_1367.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Deshpande, Amit Ajit, Rishabh Khurana, and Gurpreet Gulati. "CMR Physics." In CT and MRI in Congenital Heart Diseases, 3–27. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-6755-1_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Willsher, Richard. "CMR Note." In Export Finance, 172–73. London: Palgrave Macmillan UK, 1995. http://dx.doi.org/10.1007/978-1-349-13980-4_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Imazio, Massimo, Monica Andriani, Luisa Lobetti Bodoni, and Fiorenzo Gaita. "CMR Methodology." In Learning Cardiac Magnetic Resonance, 53–72. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-11608-8_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wright, Jeremy, and Jan Bogaert. "CMR: Basic Principles." In The ESC Textbook of Cardiovascular Imaging, 111–20. London: Springer London, 2010. http://dx.doi.org/10.1007/978-1-84882-421-8_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Peebles, Charles. "Anatomy by CMR." In Cardiovascular MR Manual, 235–40. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20940-1_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Plein, Sven. "The CMR Report." In Cardiovascular MR Manual, 241–45. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20940-1_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Engblom, Henrik, Christos G. Xanthis, Sophie I. Mavrogeni, Suzanne M. Smart, and Anthony H. Aletras. "Black-Blood CMR." In Basic Principles of Cardiovascular MRI, 161–66. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22141-0_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dharmakumar, Rohan, Behzad Sharif, and Hsin-Jung Yang. "CMR Pulse Sequences." In Basic Principles of Cardiovascular MRI, 25–40. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22141-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Plein, Sven, John Greenwood, and John Phillip Ridgway. "Anatomy by CMR." In Cardiovascular MR Manual, 251–59. London: Springer London, 2010. http://dx.doi.org/10.1007/978-1-84996-362-6_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "The CMR"

1

Dancy, Luke, Daniel Bromage, and Daniel Sado. "19 Diagnostic benefits of clinical CMR." In British Cardiovascular Imaging Meeting 2018, 2–4th May 2018, Edinburgh. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-bcvi.34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

McKenney, Mark, Sarita C. Viswanadham, and Elizabeth Littman. "The CMR model of moving regions." In SIGSPATIAL '14: 22nd SIGSPATIAL International Conference on Advances in Geographic Information Systems. New York, NY, USA: ACM, 2014. http://dx.doi.org/10.1145/2676552.2676564.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shamshidov, Boris, Alex Ignatovsky, and Kostia Mandel. "Increasing Seizure Resistance of Friction Pairs Using Combined Micro Relief." In World Tribology Congress III. ASMEDC, 2005. http://dx.doi.org/10.1115/wtc2005-63469.

Full text
Abstract:
This paper presents the Combined Micro Relief (CMR) method developed by the authors. CMR is a two-step process: grooving and FriCSo lapping. The grooves, produced through plastic indentation in the metal, serve both as lubricant reservoir and debris removal means. The FriCSo lapping, done with polymer and abrasive paste, produces low roughness area, thin densified layer and increased surface participation in the contact area. In repeated tests and experiments, CMR was found to be highly effective in addressing extreme lubrication conditions such as oil starvation, boundary and mixed lubrication. CMR application results include reduction of friction and superior resistance to scuffing wear and seizure.
APA, Harvard, Vancouver, ISO, and other styles
4

Sahu, D. R., B. K. Roul, Shyamalendu M. Bose, S. N. Behera, and B. K. Roul. "Investigation of CMR Properties in Perovskite Manganites." In MESOSCOPIC, NANOSCOPIC AND MACROSCOPIC MATERIALS: Proceedings of the International Workshop on Mesoscopic, Nanoscopic and Macroscopic Materials (IWMNMM-2008). AIP, 2008. http://dx.doi.org/10.1063/1.3027159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Noginova, N., M. Bahoura, C. E. Bonner, and A. Verevkin. "Fast and slow photoresponses in CMR thin films." In CLEO 2001. Technical Digest. Summaries of papers presented at the Conference on Lasers and Electro-Optics. Postconference Technical Digest. IEEE, 2001. http://dx.doi.org/10.1109/cleo.2001.947674.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Leung, E. T. H., and J. K. Tsotsos. "Adaptive enhancement of cardiac magnetic resonance (CMR) images." In Tenth IEEE International Conference on Computer Vision (ICCV'05) Volume 1. IEEE, 2005. http://dx.doi.org/10.1109/iccv.2005.30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Romaszko, Lukasz, Alan Gao, Agnieszka Borowska, Hao Borowska, Xiaoyu Luo, and Dirk Husmeier. "Direct Learning Left Ventricular Meshes from CMR Images." In International Conference on Statistics: Theory and Applications (ICSTA'19). Avestia Publishing, 2019. http://dx.doi.org/10.11159/icsta19.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Spath, Nick B., Miquel Gomez, Russell J. Everett, Scott I. Semple, Calvin WL Chin, David E. Newby, and Marc R. Dweck. "11 CMR longitudinal strain analysis in aortic stenosis." In British Cardiovascular Imaging Meeting 2018, 2–4th May 2018, Edinburgh. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-bcvi.26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rao, Abhiram, and Prahlad G. Menon. "4D Mitral Valve Motion Analysis Using Multi-Plane Cine Cardiac MRI Reconstructions for Functional Classification of Patients With Mitral Regurgitation." In ASME 2014 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/imece2014-39910.

Full text
Abstract:
Mitral regurgitation (MR) is a common consequence of ventricular remodeling in heart failure (HF) patients with systolic dysfunction and is associated with diminished survival rates. Characterization of patient-specific anatomy and function of the regurgitant mitral valve (MV) can enhance surgical decision making in terms of medical device choice and deployment strategy for minimally invasive endovascular approaches for MV repair. As a first step toward pre-operative planning for MV repair, we examine the feasibility of using cardiac magnetic resonance (CMR) images acquired in multiple orientations to resolve leaflet function and timing. In this study, MV motion of a HF patient with ischemic heart disease exhibiting both adverse ventricular remodeling and MR was compared pre-operatively against a normal control from the Sunnybrook cardiac database, starting with manually segmented 2D MV contours from cine CMR images acquired in multiple orientations. We find that MV motion analysis from CMR imaging is feasible and anatomical reconstruction using oriented segmentations from a combination of imaging slices acquired in multiple orientations can help overcome inherent limitations of CMR image data in terms of resolving small anatomical features, owing to finite slice-thicknesses and partial volume effects.
APA, Harvard, Vancouver, ISO, and other styles
10

Yu, U., Yu V. Skrvpnyk, and B. I. Min. "Isotope effects in charge ordered colossal magnetoresistive (CMR) manganites." In IEEE International Magnetics Conference. IEEE, 1999. http://dx.doi.org/10.1109/intmag.1999.837974.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "The CMR"

1

Friedrich, S., and R. Kolagani. Total Energy CMR Production. Office of Scientific and Technical Information (OSTI), August 2008. http://dx.doi.org/10.2172/945555.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Seybold, Patricia. Designing a Customer-In CMR Environment. Boston, MA: Patricia Seybold Group, January 2004. http://dx.doi.org/10.1571/psgp1-23-04cc.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kiryukhin, V., D. Casa, B. Keimer, J. P. Hill, A. Vigliante, Y. Tomioka, and Y. Tokura. X-ray induced insulator-metal transitions in CMR manganites. Office of Scientific and Technical Information (OSTI), December 1997. http://dx.doi.org/10.2172/658155.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Frame, Katherine C., Cipriano D. Gomez, William R. Salazar, Douglas R. Mayo, Georgiana M. Vigil, William J. Crooks, and Sy Stange. CMR Shuffler System: Passive Mode Calibration and Certification Report. Office of Scientific and Technical Information (OSTI), July 2012. http://dx.doi.org/10.2172/1047091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bargelski, C. J., and D. E. Berrett. Chemical and Metallurgy Research (CMR) Sample Tracking System Design Document. Office of Scientific and Technical Information (OSTI), September 1998. http://dx.doi.org/10.2172/5081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Neumeier, J. J., M. F. Hundley, A. L. Cornelius, and K. Andres. Volume-based considerations for the metal-insulator transition of CMR oxides. Office of Scientific and Technical Information (OSTI), March 1998. http://dx.doi.org/10.2172/658143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Adams, K., S. D. Matthews, and M. A. McQueen. Recommendations for a Software Quality Assurance Plan for the CMR Facility at LANL. Office of Scientific and Technical Information (OSTI), October 1998. http://dx.doi.org/10.2172/5075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Alexis Lavine, Donathan Krier, Florie Caporuscio, and Jamie Gardner. Stratigraphy and Geologic Structure at the Chemical and Metallurgy (CMR) Building, Technical Area 3, Los Alamos National Laboratory. Office of Scientific and Technical Information (OSTI), October 1998. http://dx.doi.org/10.2172/1682.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Banerjee, Satyajit. Imaging the Spatial Distribution of Transport Currents and the Phenomenon of Nanoscale Phase Separation Phenomenon in CMR Materials. Fort Belvoir, VA: Defense Technical Information Center, September 2007. http://dx.doi.org/10.21236/ada473092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dirisu, Osasuyi. Understanding barriers to clinical management of rape (CMR) services among survivors of rape in crisis settings in Borno state. Population Council, 2020. http://dx.doi.org/10.31899/rh12.1012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'The CMR' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography